Clinical Trial Update: Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating Picibanil (OK-432) sclerotherapy in children with macrocystic lymphatic malformations has completed Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphatic Malformations

Drugs mentioned

• Picibanil (OK-432) (OK-432)

Snippet

Sponsor: University of Iowa | Conditions: Lymphatic Malformations | Phase 2, Phase 3 | Status: COMPLETED